Fig. 3

Amelioration of CAIA development in Cxcl10 ^–/– and Cxcr3 ^–/– mice. a Experimental design of CAIA. WT, Cxcl10 ^–/–, and Cxcr3 ^–/– mice were subjected to collagen type II antibodies + LPS (CAIA) or LPS injection (control). b–d Development of CAIA was monitored for 12 days, and arthritic scores were assessed by the degree of swelling in each paw (scored 0–3). Arthritic scores in WT and Cxcl10 ^–/– mice (b, n = 5 each) and WT and Cxcr3 ^–/– mice (c, n = 5 each) subjected to CAIA. Data represent mean ± SEM. *P < 0.01; **P < 0.001 vs WT at each time point by two-way repeated-measures ANOVA followed by Bonferroni’s test. Representative photographs of CAIA-induced paw swelling on day 9 (d). e, f Representative micro-CT images and quantification of bone surface erosion in the hind paws from WT and Cxcl10 ^–/– mice (e; n = 5 each group) and WT and Cxcr3 ^–/– mice (f, n = 5 each group) on day 12. Arrows indicate bone erosions. Data represent mean ± SEM. *P < 0.001 by one-way ANOVA followed by Dunnett’s test. LPS lipopolysaccharide, WT wild-type, CXCL10 C-X-C motif chemokine 10, Cxcr3 CXC chemokine receptor 3, CAIA collagen antibody-induced arthritis